In addition, eligibility criteria were relaxed to allow enrolment of patients with pancreatic cancer, colorectal cancer, and BRAF V600E mutant melanoma who had progressed on BRAF inhibitors in the Mod and Sev cohorts. Here, BRAF is linked to pancreatic neoplasm.